U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07323784) titled 'A Phase 2 Study of NTX-1472 in Social Anxiety Disorder' on Jan. 06.
Brief Summary: The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are:
* Is NTX-1472 safe and well tolerated in adults with SAD?
* How effectively does NTX-1472 treat adults with SAD?
Researchers will compare the effects of NTX-1472 with matching placebo (a look-alike capsule that contains no drug).
Participants will:
* Take NTX-1472 or matching placebo every day for 8 weeks
* Visit the clinic 6 times ...